Early Onset Post-transplant Lymphoproliferative Disorder Presenting with Diarrhea Post-orthotopic Liver Transplant Treated Successfully with Single Rituximab Agent

Post-transplant lymphoproliferative disorder (PTLD) is a rare complication seen in hematologic stem cell (HSC) and solid organ transplantation that results from immune suppressant medications needed to prevent allograft rejection. Epstein-Barr virus (EBV) has been implicated in a majority of these cases, specifically with B-cell-predominant lymphomas. We present a 57-year-old female who underwent an orthotopic liver transplant and presented with diarrhea and weight loss. At the time of transplantation, the patient's quantitative EBV titers were negative; however, repeat titers during her admission were positive. Infectious etiologies for diarrhea were negative so a colonoscopy was pursued which revealed large ulcerated areas and biopsies consistent with monomorphic, diffuse large B-cell lymphoma, plus EBV. Imaging revealed multiple areas below the diaphragm of lymphadenopathy. The patient was started on rituximab and antivirals, and immune suppressive medications were decreased with a resolution of her symptoms. PTLD after any transplantation can be difficult to diagnose, given the wide range of presenting symptoms. Identifying patients who are at high risk for developing PTLD may lead to a more timely diagnosis to initiate treatment and decrease mortality risk.

[1]  M. Saif,et al.  Post-transplantation lymphoproliferative disorder with gastrointestinal involvement , 2018, Annals of gastroenterology.

[2]  I. Obiorah,et al.  An Unusual Posttransplant T-cell Lymphoma After Liver Transplantation: A Case Report. , 2017, Transplantation proceedings.

[3]  J. Pomposelli,et al.  Chapter 120 – Early and late complications of liver transplantation , 2017 .

[4]  D. Dierickx,et al.  Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now? , 2015, World journal of gastroenterology.

[5]  K. Mumtaz,et al.  Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations. , 2015, Canadian journal of gastroenterology & hepatology.

[6]  P. Komolmit,et al.  Post liver transplantation lymphoproliferative disorder mimics recurrence of hepatocellular carcinoma , 2013, BMJ Case Reports.

[7]  H. Tawbi,et al.  Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective , 2012, Critical Care.

[8]  S. Kenney,et al.  The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBV-PK, but Not the Thymidine Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral Production , 2010, Journal of Virology.

[9]  R. Stuart,et al.  Posttransplantation lymphoproliferative disorder—The great mimic in liver transplantation: Appraisal of the clinicopathologic spectrum and the role of Epstein‐Barr virus , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  G. Salles,et al.  Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. , 2006, Blood.

[11]  V. Leblond,et al.  Lymphoproliferative disorders after liver transplantation. , 2004, Journal of hepatology.

[12]  A. Demetris,et al.  Epstein‐Barr Virus—Associated Syndromes in Immunosuppressed Liver Transplant Recipients: Clinical Profile and Recognition on Routine Allograft Biopsy , 1990, The American journal of surgical pathology.

[13]  K. A. Porter Pathology of Liver Transplantation , 1969, Transplantation reviews.